lobbying_activities: 2102542
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2102542 | 40ae77a2-61f3-4e92-889c-c90dad2c92f0 | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2018 | first_quarter | PHA | H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access and affordability of prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs) S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Issues related to lowering the price of prescription medications in the United States. | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 60000 | 0 | 0 | 2018-04-06T15:08:50.833000-04:00 |